Haw Par (H02.SI): A $3B Singapore Conglomerate Where the Market Prices Tiger Balm at Less Than Zero

$H02.SI. Haw Par is a 3.0 billion dollar Singapore-listed conglomerate and a long-running James Hay favourite at Pangolin Asia Fund. Add together its UOB shares, UOL shares, net cash, and investment properties: you arrive at roughly 3.35 billion dollars of identifiable asset value.

Which means the market is pricing Tiger Balm, a 117-year-old global brand, at less than zero.

That single observation is the entire compressed thesis. The rest of this post is about whether the discount is a permanent value trap, or the price of entry into one of Asia's most durable family dynasties at a moment of generational transition.

Tiger Balm Is Not a Product. It Is a Habit.

Tiger Balm is sold in 100 plus countries. The formula has barely changed since 1909. It works on everything from migraines to mosquito bites to muscle aches. For an entire generation of Asian households, it has been a default kitchen-drawer item alongside Panadol and antiseptic ointment.

The honest caveat is that Tiger Balm is more ubiquitous among the older generation than the young. The brand is operating against the same demographic and category trends that pressure every legacy OTC consumer staple. That said, the global footprint, the brand recognition, and the operating margins are real. The market's decision to value the asset at negative book is itself a market judgement, not a business reality.

"The deepest moats in Asian small-caps are not in the operating businesses. They are in the architecture of family control."

The Real Asset: A Wee Family Cross-Holding Node

Haw Par holds 74.85 million UOB shares (one of Singapore's top three banks) and 72.04 million UOL shares (a Singapore property developer). Together, those two holdings are worth more than the entire market capitalisation of Haw Par itself. The operating Tiger Balm business comes essentially free.

Why does this structure exist? Because Haw Par is not really a Tiger Balm company with some investments on the side. It is a cross-holding node inside the Wee family's broader Singapore capital structure. UOB at the top, UOL adjacent, Haw Par holding stakes in both, the family holding stakes in Haw Par. The architecture stabilises control across multiple listed entities at a level that direct ownership alone cannot reach.

The deepest moat in this business is not Tiger Balm. It is the architecture of family control. Understanding that changes how you interpret everything else, including the persistent NAV discount, the conservative dividend policy, and the absence of buybacks. We covered the broader category of structural moats in our explainer on what an economic moat actually is.

The Quiet Catalyst: Succession

The patriarch, Wee Cho Yaw, passed away in February 2024 at age 95. He had been the steward of the Wee family capital structure for over half a century. New leadership at the family level tends to be less reflexively conservative with idle balance sheets than the founder generation was.

The first visible signal was the S$1.00 special dividend declared in May 2025. That was the first special dividend in memory. It signalled that the post-Wee-Cho-Yaw generation is more comfortable returning capital than the previous one. It is one data point. It is also exactly the kind of data point that, in family-controlled Asian conglomerates, tends to lead to more of the same over the following five to ten years rather than being a one-off.

Operations Are Quietly Compounding

Underneath the headline NAV discount, the operating business is not standing still. The Johor Bahru plant is commissioning from 2025, expanding ASEAN production capacity in a geography where Tiger Balm has structurally stronger demand than in Western markets. Management flagged “strong demand in ASEAN, Europe, and other regions” in the FY2024 disclosures. H1 2025 delivered roughly 7 percent revenue growth.

Seven percent revenue growth from a 117-year-old OTC consumer brand is genuinely respectable. It is not a hypergrowth story. It is the kind of mid-single-digit organic compounding that, paired with capital returns, produces meaningful per-share progress over a decade.

Capital Returns: Direction Is Changing

The regular dividend stepped from S$0.30 to S$0.40 per share (a 33 percent lift). Then the S$1.00 special dividend in May 2025. That is two consecutive years of capital-return policy getting more generous. The direction of travel is what matters.

The caveat is that S$730 million of net cash still sits idle on the balance sheet, and there is no buyback programme despite a deep NAV discount that would make a buyback mechanically accretive. Generous, not aggressive. The Wee-family playbook has never been aggressive, and probably never will be. But generous and getting more generous is a meaningfully better setup than dormant and staying dormant.

The MoatMap Scorecard: Q64 V41 M55, StockRank 80

Here is the Haw Par MoatMap StockRank:

• Quality: 64/100. Solid, helped meaningfully by the fortress balance sheet and the steady cash conversion from Tiger Balm.
• Value: 41/100. P/E of 14.4x, P/B of 0.89x. Trading below book on a business that holds bank shares, property shares, net cash, and a 117-year-old consumer brand. Not classically screen-deep cheap on PE, but structurally cheap on assets.
• Momentum: 55/100. Middle of the pack.
• Composite StockRank: 80/100. Strong rating overall. The Quality and balance-sheet characteristics are doing the heavy lifting.

Debt-to-equity sits at 0.01x. This is a fortress balance sheet trading below book in a market that systematically discounts Asian family conglomerates. The factor profile rewards exactly that combination.

Value Trap or Dynasty Entry Fee?

Worth noting: Haw Par is a long-time core holding of James Hay's Pangolin Asia Fund, a manager known specifically for the patience required to compound in Southeast Asian family-controlled small and mid-caps. Quality patient capital being there for two decades does not guarantee future returns. It is a signal worth weighing against the shallower interpretation that the NAV discount is just a permanent dead-money problem.

So here is the question. Is a permanent NAV discount a value trap, or simply the entry fee to one of Asia's most durable family dynasties, now in generational transition with capital returns visibly inflecting in a more shareholder-friendly direction?

The honest answer is that the discount has been permanent for decades. If you are buying expecting the gap to close in 18 months, you will be disappointed. If you are buying expecting a mid-single-digit operating compounder paired with gradually rising capital returns, paired with the option value of a meaningful re-rating if the post-Wee generation ever decides to formally simplify the structure, that is a defensible long-duration thesis with a margin of safety embedded in the balance sheet itself.

The Bottom Line

Haw Par is a Singapore quality-and-value compounder priced below book with a hidden Tiger Balm brand worth more than the market is pricing it at. The discount is structural. The capital return policy is improving. The succession catalyst is real. The factor profile rewards exactly this kind of asymmetric setup. Patient capital has been there for years.

For investors using Haw Par as a single-name idea, our guide to reviewing your portfolio for weak spots is the right framework for thinking about long-duration dividend-cathedral positions that may be permanently discounted by the market.

For the full breakdown including the UOB and UOL stake math, the Wee family cross-holding map, the Johor Bahru expansion, and the post-succession capital-return roadmap, the Haw Par Deep Dive is the place to go.

Disclosure: this article is for informational purposes only and is not investment advice.